Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RA) lower the risk of kidney outcomes in type 2 diabetes on average.
- Individual responses to GLP-1RA therapy may vary significantly among patients.
- Identifying specific patient subgroups could enhance the effectiveness of GLP-1RA therapy for kidney health.
- The study focuses on determining which patients are more likely to benefit from GLP-1RA in terms of kidney outcomes.
Simplified